Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Entropy NeurodynamicsTYPTF -23.08% Cash-to-Debt is 9.64 as of Dec. 2025, which is 8% below its 10-year median of 10.51. The stock has 6 warning signs investors should review. Among 1,343 Biotechnology companies, Entropy Neurodynamics ranks better than 53.83% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Entropy Neurodynamics's cash to debt ratio for the quarter that ended in Dec. 2025 was 9.64.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Entropy Neurodynamicscould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Entropy Neurodynamics's Cash-to-Debt or its related term are showing as below:
TYPTF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.07 Med: 10.51 Max: No Debt
Current: 9.65
During the past 7 years, Entropy Neurodynamics's highest Cash to Debt Ratio was No Debt. The lowest was 1.07. And the median was 10.51.
TYPTF's Cash-to-Debt is ranked better than 53.83% of 1343
companies
in the Biotechnology industry
Industry Median: 7.25
vs TYPTF: 9.65
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Entropy Neurodynamics Cash-to-Debt Related Terms
Entropy Neurodynamics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Entropy Neurodynamics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
TYPTF vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, Entropy Neurodynamics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entropy Neurodynamics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entropy Neurodynamics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Entropy Neurodynamics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entropy Neurodynamics (TYPTF) has a Cash-to-Debt of 9.64 as of Dec. 2025. This is near median its historical median of 10.51. Over the past decade, Entropy Neurodynamics' Cash-to-Debt has ranged from 1.07 to 10,000.00. According to the industry distribution chart, Entropy Neurodynamics ranks #620 out of 1343 companies in the Biotechnology industry, placing it in the top 46.2%.
Is Entropy Neurodynamics' Cash-to-Debt too high?
Entropy Neurodynamics' current Cash-to-Debt of 9.64 is near median its 10-year median of 10.51. Over the past 10 years, this metric has ranged from a low of 1.07 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.25. Entropy Neurodynamics' value of 9.64 is 33% above this industry median. Based on the distribution chart, Entropy Neurodynamics ranks #620 out of 1343 companies in the Biotechnology industry, which is above the industry midpoint.
How does Entropy Neurodynamics' Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Entropy Neurodynamics ranks #620 out of 1343 companies for Cash-to-Debt. This puts Entropy Neurodynamics in the upper half of its industry. The industry median Cash-to-Debt is 7.25. Entropy Neurodynamics' value of 9.64 is 33% above this benchmark. Historically, Entropy Neurodynamics' own Cash-to-Debt has ranged from 1.07 to 10,000.00 over the past decade. While the company's 10-year median is 10.51 vs. the industry median of 7.25, Entropy Neurodynamics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.25, based on 1,343 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Entropy Neurodynamics's current Cash-to-Debt of 9.64 is 33% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entropy Neurodynamics's current Cash-to-Debt is 9.64, which is near median its own 10-year median of 10.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (TYPTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.03 — trading 150% above its estimated fair value. The current Cash-to-Debt is 9.64, which is near median its 10-year median of 10.51 and 33% above the Biotechnology industry median of 7.25. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Entropy Neurodynamics (TYPTF), the current Cash-to-Debt is 9.64 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TYPTF has been successfully added to your 
